Spin-out raises £7.5m for novel treatment for blocked arteries
IsomAb – a University of Nottingham spin-out pioneering a new treatment for diabetics at risk of amputation – has raised £7.5m (US$9.4m) in a funding round led by Broadview Ventures and backed by MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund